Updates are available Correction dated 2026-03-26

Article History

Accepted: 19 August 2024

First Online: 7 October 2024

Change Date: 18 March 2026

Change Type: Update

Change Details: The original article has been corrected. Figure 5 has been revised. Captions are updated for Figs 3 and 5.

Change Date: 26 March 2026

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s40263-026-01285-w

Declarations

:

: This research was entirely supported by Supernus Pharmaceutials, Inc. Open acces publication was funded by Supernus Pharmaceutials, In.

: A.C. has received research support from, served as a consultant or speaker for, or served on an advisory board for Aardvark, Adlon, Akili Interactive, Allergan, Alora, Arbor, Axsome, Aytu, Cingulate Therapeutics, Corium, Emalex, Ironshore, KemPharm, Lumos, Neurovance, Noven, Otsuka, Purdue, Rhodes, Sunovion, Takeda Pharmaceuticals, Tris, and Supernus Pharmaceuticals, Inc. A.J.C. has received research support from, served as a consultant or speaker for, or served on an advisory board for AbbVie (Allergan), Acadia, Aevi Genomic Medicine, Akili Interactive, Arbor Pharmaceuticals, Atentiv, Axsome, Boehringer Ingelheim, Biogen, BioXcel, Cerevel, Cingulate Therapeutics, Corium, Eli Lilly, Intra-Cellular Therapies, Ironshore Pharmaceuticals, Janssen, Karuna, KemPharm, LivaNova, Lundbeck, MedAvante-ProPhase, Neos Therapeutics (now Aytu BioPharma), Neumora, Neurocrine, NeuroSigma, Neurovance, NLS Pharma, Noven, Otsuka, Purdue Canada, Rhodes Pharmaceuticals, Relmada Therapeutics, Inc., Sage Therapeutics, Sumitomo (Sunovion), Supernus Pharmaceuticals, Inc., Takeda Pharmaceuticals (Shire), Teva, Thynk Health, Tris Pharma, and VistaGen. L.A.A. has received grant and research support from Otsuka, Takeda Pharmaceuticals, and Corium Pharmaceuticals; has served as a consultant to Bracket, Major League Baseball, the National Football League, Otsuka Pharmaceuticals, Takeda Pharmaceuticals, Supernus Pharmaceuticals, Inc., and SUNY; and has received loyalty payments (as inventor) since 2004 from NYU for the license of adult ADHD scales and training materials. N.F., K.A., Z.M.C., A.E.F., and J.R. are employees of Supernus Pharmaceuticals, Inc.

: The study was approved by an institutional review board (WCG IRB #20192701) and conducted in accordance with the Declaration of Helsinki and the International Council for Harmonisation Good Clinical Practice Guidelines.

: Each participant provided written informed consent prior to enrollment.

: Not applicable.

: The data are not available in a repository, but data will be made upon reasonable request directed to jrubin@supernus.com.

: Not applicable.

: Conceptualization and design: J.R., A.J.C., and A.C. Methodology and data collection: J.R. Analysis and interpretation: J.R., A.J.C., L.A., A.C., and A.E.F. Final data assurance: K.A., Z.M.C., and A.E.F. Medical writing: A.E.F. All authors have read, reviewed, and approved the original drafts and final submitted version of the manuscript and agree to be held accountable for the work.